A strategy for risk mitigation of antibodies with fast clearance-Reference-Cited by-同舟云学术

A strategy for risk mitigation of antibodies with fast clearance

Published:2012-11 Issue:6 Volume:4 Page:753-760
ISSN:1942-0862
Container-title:mAbs
language:en
Short-container-title:mAbs

Author:

Hötzel Isidro,Theil Frank-Peter,Bernstein Lisa J.,Prabhu Saileta,Deng Rong,Quintana Leah,Lutman Jeff,Sibia Renuka,Chan Pamela,Bumbaca Daniela,Fielder Paul,Carter Paul J.,Kelley Robert F.

Publisher

Informa UK Limited

Subject

Immunology,Immunology and Allergy

Link

http://www.tandfonline.com/doi/pdf/10.4161/mabs.22189

Reference31 articles.

1. Marketed therapeutic antibodies compendium

2. Monoclonal Antibody Pharmacokinetics and Pharmacodynamics

3. Elimination mechanisms of therapeutic monoclonal antibodies

4. Target-mediated drug disposition and dynamics

5. Pharmacokinetics and Pharmacodynamics of Monoclonal Antibodies

Cited by 213 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Coupling cation and anion exchange chromatography for fast separation of monoclonal antibody charge variants;Journal of Chromatography A;2024-09

2. Cellular Neonatal Fc Receptor Recycling Efficiencies can Differentiate Target-Independent Clearance Mechanisms of Monoclonal Antibodies;Journal of Pharmaceutical Sciences;2024-09

3. Assessment and incorporation of in vitro correlates to pharmacokinetic outcomes in antibody developability workflows;mAbs;2024-07-31

4. Utility of Cellular Measurements of Non-Specific Endocytosis to Assess the Target-Independent Clearance of Monoclonal Antibodies;Journal of Pharmaceutical Sciences;2024-07

5. Molecular surface descriptors to predict antibody developability: sensitivity to parameters, structure models, and conformational sampling;mAbs;2024-06-10